Fortis Hospital, India
6
0
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
Role: collaborator
How Well do we Feed the Critically Ill Patients
Role: collaborator
A Prescription Audit of Inpatient Department of Super Speciality Hospital in National Capital Region of India
Role: collaborator
Palm Tocotrienols in Chronic Hemodialysis (USA)
Role: collaborator
Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy
Role: lead
Can Changes in Velocity Time Integral Serve as a Sensitive Indicator for Monitoring Changes in Stroke Volume ?
Role: lead
All 6 trials loaded